JP2000509249A - シトクロムp450を形質導入するレトロウイルスベクター - Google Patents
シトクロムp450を形質導入するレトロウイルスベクターInfo
- Publication number
- JP2000509249A JP2000509249A JP9534051A JP53405197A JP2000509249A JP 2000509249 A JP2000509249 A JP 2000509249A JP 9534051 A JP9534051 A JP 9534051A JP 53405197 A JP53405197 A JP 53405197A JP 2000509249 A JP2000509249 A JP 2000509249A
- Authority
- JP
- Japan
- Prior art keywords
- cell line
- vector
- replication
- packaging cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 title claims abstract description 108
- 230000001177 retroviral effect Effects 0.000 title claims abstract description 92
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 title claims abstract description 43
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 title claims description 21
- 230000002463 transducing effect Effects 0.000 title description 2
- 230000001105 regulatory effect Effects 0.000 claims abstract description 31
- 230000001939 inductive effect Effects 0.000 claims abstract description 13
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 190
- 238000004806 packaging method and process Methods 0.000 claims description 55
- 241001430294 unidentified retrovirus Species 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 241000700605 Viruses Species 0.000 claims description 35
- 229940002612 prodrug Drugs 0.000 claims description 25
- 239000000651 prodrug Substances 0.000 claims description 25
- 239000002245 particle Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 210000004881 tumor cell Anatomy 0.000 claims description 17
- 241000282414 Homo sapiens Species 0.000 claims description 14
- 241000713333 Mouse mammary tumor virus Species 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 10
- 230000010076 replication Effects 0.000 claims description 10
- 241000282326 Felis catus Species 0.000 claims description 9
- 229960001101 ifosfamide Drugs 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 229960004397 cyclophosphamide Drugs 0.000 claims description 6
- 230000010354 integration Effects 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 230000002950 deficient Effects 0.000 claims description 5
- 210000005075 mammary gland Anatomy 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 241000713821 Mason-Pfizer monkey virus Species 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 241000711517 Torovirus Species 0.000 claims description 4
- 238000005538 encapsulation Methods 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 101710167917 Carbonic anhydrase 2 Proteins 0.000 claims description 3
- 102100024633 Carbonic anhydrase 2 Human genes 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000004043 responsiveness Effects 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- 102000008192 Lactoglobulins Human genes 0.000 claims description 2
- 108010060630 Lactoglobulins Proteins 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 101150033242 lpxC gene Proteins 0.000 claims 1
- 101150016099 omcA gene Proteins 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 108010020076 Cytochrome P-450 CYP2B1 Proteins 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 239000007900 aqueous suspension Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 101150053185 P450 gene Proteins 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000012679 serum free medium Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102000018832 Cytochromes Human genes 0.000 description 5
- 108010052832 Cytochromes Proteins 0.000 description 5
- 101710087237 Whey acidic protein Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 241000714266 Bovine leukemia virus Species 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000981 bystander Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000714165 Feline leukemia virus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 241001068263 Replication competent viruses Species 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012537 formulation buffer Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 2
- 239000012145 high-salt buffer Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZPSOKQFFOYYPKC-UHFFFAOYSA-N 7-pentoxyphenoxazin-3-one Chemical compound C1=CC(=O)C=C2OC3=CC(OCCCCC)=CC=C3N=C21 ZPSOKQFFOYYPKC-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000694440 Colpidium aqueous Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- -1 GCV monophosphate Chemical class 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101150093715 P4 gene Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 241001492360 Retroviral provirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 108700042475 glucokinase regulatory Proteins 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004712 monophosphates Chemical group 0.000 description 1
- PZNOBXVHZYGUEX-UHFFFAOYSA-N n-prop-2-enylprop-2-en-1-amine;hydrochloride Chemical compound Cl.C=CCNCC=C PZNOBXVHZYGUEX-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
- C12N9/0079—Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.標的細胞特異的な制御要素もしくはプロモーター、またはX線誘導性プロ モーターの転写調節下にあるシトクロムP450遺伝子を担持する複製欠損レトロ ウイルスベクター。 2.請求項1に記載の複製欠損レトロウイルスベクターであって、該ベクター がU3-R-U5構造の5'LTR領域;コード配列および非コード配列から選択され た一以上の配列;および完全または部分的に欠失したU3領域であって、標的細 胞特異的な制御要素もしくはプロモーター、またはX線誘導性プロモーターを含 有するポリリンカー配列によって置換され、RおよびU5領域が続いている3'L TR領域を具備し、少なくとも一つのコード配列がシトクロムP450をコードし ていることを特徴とする複製欠損レトロウイルスベクター。 3.請求項1または2に記載の複製欠損レトロウイルスベクターであって、標 的細胞特異的な制御要素またはプロモーターが、WAP、MMTV、β−ラクト グロブリンおよびカゼイン特異的制御要素およびプロモーター、炭酸脱水酵素II およびβ−グルコキナーゼ制御要素およびプロモーターを含む膵臓特異的な制御 要素およびプロモーター、免疫グロブリンおよびMMTVリンパ球特異的制御要 素およびプロモーターを含むリンパ球特異的な制御要素およびプロモーター、グ ルココルチコイドホルモンに対する応答性を与えるかまたは乳腺に対して発現を 指令するMMTV特異的な制御要素およびプロモーターからなる群の一以上の要 素から選択される複製欠損レトロウイルスベクター。 4.請求項1〜3の何れか1項に記載の複製欠損レトロウイルスベクターであ って、前記LTR領域が、MLV、MMTV、MSV、SIV、HIV、HTL V、FIV、FeLV、BLV、およびMPMVのLTRからなる群の少なくと も一つの要素から選択されている複製欠損レトロウイルスベクター。 5.請求項1〜4に記載の複製欠損レトロウイルスベクターであって、前記レ トロウイルスベクターがBAGベクターまたはpLXSNベクターをベースとす る複製欠損レトロウイルスベクター。 6.請求項5に記載の複製欠損レトロウイルスベクターであって、前記レトロ ウイルスベクターが実施例1の記載のように調製されたpLX2B1である複製欠 損 レトロウイルスベクター。 7.請求項5に記載の複製欠損レトロウイルスベクターであって、前記レトロ ウイルスベクターが実施例2の記載のように調製されたpc3/2B1である複製欠損 レトロウイルスベクター。 8.請求項1〜5の何れか1項に記載の複製欠損レトロウイルスベクターであ って、レトロウイルスの組込みに関与するレトロウイルス配列が改変され、また は少なくとも部分的に欠失している複製欠損レトロウイルスベクター。 9.請求項1に記載の複製欠損レトロウイルスベクターであって、前記制御要 素またはプロモーターがトランス作用分子によって調節され得る複製欠損レトロ ウイルスベクター。 10.請求項1〜9に記載の複製欠損レトロウイルスベクターをトランスフェ クトしたパッケージング細胞株であって、該パッケージング細胞株が、前記レト ロウイルスベクターをパッケージするために必要なタンパク質をコードするレト ロウイルスまたは組換えレトロウイルス構造物を少なくとも一つ含有しているパ ッケージング細胞株。 11.請求項10に記載のパッケージング細胞株であって、該パッケージング 細胞株が謡歯類、イヌ、ネコ、またはヒト由来であり、ヒト組織と組織適合性が あるパッケージング細胞株。 12.請求項10に記載のパッケージング細胞株であって、パッケージング細 胞株がpsi-2、psi-Crypt、psi-AM、GP+E-86、PA317、およびGP+envA M-12からなる群から選択されるパッケージング細胞株。 13.請求項10〜12の何れか1項に記載のパッケージング細胞株を適切な 条件下で培養した後、産生された組換えレトロウイルス粒子を任意に単離するこ とにより産生される組換えレトロウイルス粒子。 14.請求項13に記載の組換えレトロウイルス粒子を具備する薬学的組成物 。 15.請求項10〜12の何れか1項に記載のパッケージング細胞株を具備す る薬学的組成物。 16.パッケージング細胞株によって産生された組換えレトロウイルス粒子 を通過させることができる多孔性の膜に封入された請求項10〜12の何れか1 項に記載のパッケージング細胞株。 17.セルロース硫酸およびポリジメチルジアリルアンモニウムによって形成 された複合体中に封入されている請求項16に記載のパッケージング細胞株。 18.請求項13に記載の組換えレトロウイルス粒子、請求項10〜12に記 載のパッケージング細胞株、または請求項16〜17の何れか1項に記載の封入 されたパッケージング細胞株、およびシトクロムP450によって活性化される癌 のプロドラッグを同時にまたは時問を隔てて、本方法を必要としている患者に治 療的有効量投与することを具備する腫瘍細胞の除去法。 19.前記腫瘍細胞が乳癌または膵臓癌細胞である請求項18に記載の方法。 20.癌のプロドラッグがシクロフォスファミドまたはイフォスファミドであ る請求項18に記載の方法。 21.組換えレトロウイルス粒子、パッケージング細胞株、もしくは封入され たパッケージング細胞株を注射によって、または腫瘍中もしくは腫瘍部位に移植 することによって投与し、且つ癌のプロドラッグを全身または局所的に投与する 請求項18〜20に記載の方法。 22.腫瘍細胞を除去するのに有用な薬学的組成物を調製するための請求項1 3に記載の組換えレトロウイルス粒子、請求項10〜12の何れか1項に記載の パッケージング細胞株、または請求項16〜17の何れか1項に記載の封入され たパッケージング細胞株の使用。 23.標的細胞特異的な制御要素もしくはプロモーター、またはX線誘導性プ ロモーターの転写調節下にあるシトクロムP450遺伝子を担持する、ヒトケノム 中に組み込まれたレトロウイルスプロウイルス。 24.標的細胞特異的な制御要素もしくはプロモーター、またはX線誘導性プ ロモーターの転写調節下にあるシトクロムP450遺伝子を含有するヒト細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK35296 | 1996-03-27 | ||
DK0352/96 | 1996-03-27 | ||
PCT/EP1997/001585 WO1997035994A2 (en) | 1996-03-27 | 1997-03-27 | Cytochrome p450 transducing retroviral vectors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000509249A true JP2000509249A (ja) | 2000-07-25 |
JP2000509249A5 JP2000509249A5 (ja) | 2004-12-02 |
JP4229982B2 JP4229982B2 (ja) | 2009-02-25 |
Family
ID=8092560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53405197A Expired - Lifetime JP4229982B2 (ja) | 1996-03-27 | 1997-03-27 | シトクロムp450を形質導入するレトロウイルスベクター |
Country Status (19)
Country | Link |
---|---|
US (1) | US6893634B1 (ja) |
EP (1) | EP0892852B1 (ja) |
JP (1) | JP4229982B2 (ja) |
AT (1) | ATE309383T1 (ja) |
AU (1) | AU713382B2 (ja) |
CA (1) | CA2250173A1 (ja) |
CZ (1) | CZ288074B6 (ja) |
DE (1) | DE69730595D1 (ja) |
DK (1) | DK0892852T3 (ja) |
ES (1) | ES2253775T3 (ja) |
HU (1) | HU221349B1 (ja) |
IL (1) | IL125795A0 (ja) |
NO (1) | NO325392B1 (ja) |
NZ (1) | NZ331765A (ja) |
PL (1) | PL188323B1 (ja) |
RU (2) | RU2185821C2 (ja) |
SI (1) | SI0892852T1 (ja) |
SK (1) | SK282744B6 (ja) |
WO (1) | WO1997035994A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0835137T3 (da) | 1995-06-27 | 2006-03-06 | Bavarian Nordic As | Indkapslede celler, som danner viruspartikler |
US6540995B1 (en) | 1996-03-27 | 2003-04-01 | Bavarian Nordic Research Institute Gmbh | Encapsulated cells producing cytochrome P450 |
PL188323B1 (pl) | 1996-03-27 | 2005-01-31 | Bavarian Nordic As | Kapsuła zawierająca komórki i jej zastosowanie oraz kompozycja i środek farmaceutyczny |
WO2000017366A2 (en) * | 1998-09-21 | 2000-03-30 | Transgene S.A. | Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug |
GB0400443D0 (en) | 2004-01-09 | 2004-02-11 | Oxford Biomedica Ltd | Cascade |
GB9900009D0 (en) * | 1999-01-04 | 1999-02-24 | Ml Lab Plc | Gene therapy |
EP1141318B1 (en) * | 1999-01-04 | 2006-07-05 | Innovata PLC | P450 / acetaminophen gdept for cancer treatment |
GB0010105D0 (en) * | 2000-04-26 | 2000-06-14 | Ml Lab Plc | Cell ablation |
AU2002336162A1 (en) * | 2001-09-21 | 2003-04-01 | Oxford Biomedica (Uk) Limited | Pseudotyped retroviral vector system |
GB201408233D0 (en) | 2014-05-09 | 2014-06-25 | Austrianova Singapore Pte Ltd | Use of polyanionic composition |
MX2015006813A (es) * | 2015-05-29 | 2016-11-28 | Univ Nac Autónoma De México | Nanoparticulas biocataliticas cyp-p22 con actividad citocromo p450 para la activacion de profarmacos. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989011539A1 (en) | 1988-05-17 | 1989-11-30 | Sloan-Kettering Institute For Cancer Research | Retroviral vector |
WO1994029437A1 (en) | 1993-06-07 | 1994-12-22 | University Of Medicine & Dentistry Of New Jersey | Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors |
US5688773A (en) * | 1994-08-17 | 1997-11-18 | The General Hospital Corporation | Method of selectively destroying neoplastic cells |
RU2199585C2 (ru) | 1994-09-02 | 2003-02-27 | ГСФ-Форшунгсцентрум фюр Умвельт унд Гезундхайт ГмбХ | Ретровирусная векторная конструкция, подвергающаяся промоторной конверсии, способ введения гомологичных или гетерологичных нуклеотидных последовательностей в человеческие или животные клетки in vitro и/или in vivo, рекомбинантная ретровирусная частица, фармацевтическая композиция для генной терапии |
DK0835137T3 (da) | 1995-06-27 | 2006-03-06 | Bavarian Nordic As | Indkapslede celler, som danner viruspartikler |
WO1997009440A1 (en) * | 1995-09-06 | 1997-03-13 | Bavarian Nordic Research Institute A/S | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells |
PL188323B1 (pl) | 1996-03-27 | 2005-01-31 | Bavarian Nordic As | Kapsuła zawierająca komórki i jej zastosowanie oraz kompozycja i środek farmaceutyczny |
-
1997
- 1997-03-27 PL PL97329071A patent/PL188323B1/pl not_active IP Right Cessation
- 1997-03-27 RU RU98119459/14A patent/RU2185821C2/ru not_active IP Right Cessation
- 1997-03-27 SK SK1323-98A patent/SK282744B6/sk not_active IP Right Cessation
- 1997-03-27 CZ CZ19983050A patent/CZ288074B6/cs not_active IP Right Cessation
- 1997-03-27 AU AU23827/97A patent/AU713382B2/en not_active Expired
- 1997-03-27 SI SI9730726T patent/SI0892852T1/sl unknown
- 1997-03-27 EP EP97919307A patent/EP0892852B1/en not_active Expired - Lifetime
- 1997-03-27 JP JP53405197A patent/JP4229982B2/ja not_active Expired - Lifetime
- 1997-03-27 CA CA002250173A patent/CA2250173A1/en not_active Abandoned
- 1997-03-27 WO PCT/EP1997/001585 patent/WO1997035994A2/en active IP Right Grant
- 1997-03-27 IL IL12579597A patent/IL125795A0/xx not_active IP Right Cessation
- 1997-03-27 DE DE69730595T patent/DE69730595D1/de not_active Expired - Lifetime
- 1997-03-27 ES ES97919307T patent/ES2253775T3/es not_active Expired - Lifetime
- 1997-03-27 NZ NZ331765A patent/NZ331765A/en not_active IP Right Cessation
- 1997-03-27 HU HU9904116A patent/HU221349B1/hu not_active IP Right Cessation
- 1997-03-27 AT AT97919307T patent/ATE309383T1/de not_active IP Right Cessation
- 1997-03-27 RU RU2002103465/15A patent/RU2223788C2/ru not_active IP Right Cessation
- 1997-03-27 DK DK97919307T patent/DK0892852T3/da active
-
1998
- 1998-09-24 US US09/160,067 patent/US6893634B1/en not_active Expired - Lifetime
- 1998-09-28 NO NO19984540A patent/NO325392B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69730595D1 (de) | 2004-10-14 |
HUP9904116A3 (en) | 2001-01-29 |
JP4229982B2 (ja) | 2009-02-25 |
HU221349B1 (en) | 2002-09-28 |
PL329071A1 (en) | 1999-03-15 |
ATE309383T1 (de) | 2005-11-15 |
US6893634B1 (en) | 2005-05-17 |
EP0892852B1 (en) | 2005-11-09 |
PL188323B1 (pl) | 2005-01-31 |
HUP9904116A2 (hu) | 2000-04-28 |
IL125795A0 (en) | 1999-04-11 |
CZ305098A3 (cs) | 1999-01-13 |
AU2382797A (en) | 1997-10-17 |
WO1997035994A2 (en) | 1997-10-02 |
RU2223788C2 (ru) | 2004-02-20 |
ES2253775T3 (es) | 2006-06-01 |
NO325392B1 (no) | 2008-04-21 |
WO1997035994A3 (en) | 1997-11-20 |
AU713382B2 (en) | 1999-12-02 |
DK0892852T3 (da) | 2006-03-06 |
NZ331765A (en) | 2000-02-28 |
CA2250173A1 (en) | 1997-10-02 |
SK132398A3 (en) | 1999-04-13 |
RU2185821C2 (ru) | 2002-07-27 |
SK282744B6 (sk) | 2002-12-03 |
CZ288074B6 (cs) | 2001-04-11 |
NO984540L (no) | 1998-09-28 |
SI0892852T1 (sl) | 2006-04-30 |
EP0892852A2 (en) | 1999-01-27 |
NO984540D0 (no) | 1998-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vile et al. | Retroviruses as vectors | |
JP4733166B2 (ja) | ベクターおよびウイルスベクター、およびこれらを増殖するためのパッケージング細胞株 | |
JP4848348B2 (ja) | ウイルス粒子産生カプセル化細胞 | |
US6872528B2 (en) | Highly productive packaging lines | |
JP2000509249A (ja) | シトクロムp450を形質導入するレトロウイルスベクター | |
EP0848757B1 (en) | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells | |
US20030157070A1 (en) | High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations | |
JP2000500986A (ja) | レトロウイルスベクターおよび遺伝子治療におけるその用途 | |
US6540995B1 (en) | Encapsulated cells producing cytochrome P450 | |
JPH11502706A (ja) | シュードタイプレトロウイルス粒子 | |
JPH11503916A (ja) | 高力価組換えレトロウイルス調製物による細胞の高効率エクスビボ形質導入 | |
US8309071B2 (en) | Foamy viral envelope genes | |
EP2138584B1 (en) | Foamy viral envelope genes | |
Fassati et al. | Retroviral vectors | |
WO2005061721A1 (es) | Nuevo vector retroviral de alto titulo y metodos de transduccion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040324 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040324 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20040826 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060808 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061115 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061225 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20071025 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071025 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081104 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081203 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111212 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111212 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121212 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121212 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131212 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |